Back    Zoom +    Zoom -
<Research>G Sachs Ratings, TPs for CN Healthcare Sector (Table)
Recommend
4
Positive
10
Negative
4
Stock | Rating | Target Price (HKD)

PHARMARON (03759.HK) | Buy | 31
WUXI XDC (02268.HK) | Buy | 85.9
EDGE MEDICAL-B (02675.HK) | Buy | 81
TIGERMED (03347.HK) | Buy | 61.4
MEDBOT-B (02252.HK) | Buy | 45

Related NewsAsymchem Laboratories (06821.HK) 1Q Net Profit RMB304 million, Down 6.8%
ASYMCHEM (06821.HK) | Buy | 118.7
GUSHENGTANG (02273.HK) | Buy | 35.4 → 35.2
WUXI APPTEC (02359.HK) | Conviction List Buy | 149.7
AK MEDICAL (01789.HK) | Neutral → Buy | 7.1 → 8.4
GENSCRIPT BIO (01548.HK) | Buy | 17.14

ANGELALIGN (06699.HK) | Buy | 100 → 110
HYGEIA HEALTH (06078.HK) | Neutral | 14.3
WUXI BIO (02269.HK) | Neutral | 41
WEIGAO GROUP (01066.HK) | Buy → Neutral | 6 → 4
MICROTECH MED-B (02235.HK) | Sell → Neutral | 8.2 → 8.9

SINOPHARM (01099.HK) | Neutral | 19.83
CHINARES PHARMA (03320.HK) | Neutral | 6.03
FRONTAGE (01521.HK) | Sell | 1.01
JXR (01951.HK) | Sell | 2.29 → 2.4
SH PHARMA (02607.HK) | Sell | 10.3

Related NewsJPM: Profit-taking in China Pharma Sector Presents Good Entry Opportunity


Auto-translated by AI

AASTOCKS Financial News